Monitoring for tuberculosis drug hepatotoxicity: Moving from opinion to evidence

American Journal of Respiratory and Critical Care Medicine

Volumn 185, Issue 6, 2012, Pages 598-599

  Saukkonen, Jussi J ^a   Powell, Krista ^b   Jereb, John A ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; TUBERCULOSTATIC AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; DIRECTLY OBSERVED THERAPY; DISEASE SEVERITY; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; EDITORIAL; HUMAN; LUNG TUBERCULOSIS; MEDICAL SOCIETY; PRIORITY JOURNAL; RISK FACTOR; SAMPLE SIZE; TOXIC HEPATITIS;

ANTITUBERCULAR AGENTS; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; LIVER FUNCTION TESTS; MALE; MONITORING, PHYSIOLOGIC; PRACTICE GUIDELINES AS TOPIC; TUBERCULOSIS;

EID: 84858193839     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201112-2174ED     Document Type: Editorial

References (8)

1. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, et al.; Antituberculosis Therapy Subcommittee. An official ATS Statement: hepatotoxicity of antitiberculosis therapy. Am J Respir Crit Care Med 2006;174:935-952. (Pubitemid 44564795)
2. Shang P, Xia Y, Liu F, Wang X, Yuan Y, Hu D, Tu D, Chen Y, Deng P, Cheng S, et al. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. PLoS ONE 2011;6:e21836.
3. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003;167:1472-1477. (Pubitemid 37363354)
4. Breen RA, Miller RF, Gorsuch T, Smith CJ, Schwenk A, Holmes W, Ballinger J, Swaden L, Johnson MA, Cropley I, et al. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax 2006;61:791-794. (Pubitemid 44369404)
5. Marra F, Marra CA, Bruchet N, Richardson K, Moadebi S, Elwood RK, Fitzgerald JM. Adverse drug reactions associated with first-line antituberculosis drug regimens. Int J Tuberc Lung Dis 2007;11:868-875. (Pubitemid 47227617)
6. Chitturi S, Farrell G. Drug-induced liver disease. In: Schiff ER, Sorrell MF, MaddreyWC, editors. Schiff's diseases of the liver, 10th ed. Philadelphia: Lippincott, Williams & Wilkins; 2007. pp. 935-936.
7. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-662.
8. Singanayagam A, Sridhar S, Dhariwal J, Abdel-Aziz D, Munro K, Connell D, George P, Molyneaux P, Burroughs A, Lalvani A, et al. A comparison between two strategies for monitoring hepatic function during anti-tuberculous therapy. Am J Respir Crit Care Med 2012:185:653-659.